{ "run": { "id": "cmnr0l2vz01lep658h281cyh8", "region": "US", "assetId": "cmnr0l2v401lap658ftebod84", "ticker": "ABT", "snapshotId": "cmnr0l2vg01lcp658ppk0zgxg", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:06:14.108Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr0l2vg01lcp658ppk0zgxg", "assetId": "cmnr0l2v401lap658ftebod84", "asOf": "2026-04-08T20:02:06.000Z", "snapshot": { "asOf": "2026-04-08T20:02:06.000Z", "quote": { "asOf": "2026-04-08T20:02:06.000Z", "open": null, "price": 103.56, "dayLow": 101.31, "volume": 8293618, "dayHigh": 103.835, "currency": "USD", "prevClose": 101.83, "week52Low": 100.88, "week52High": 139.06 }, "fundamentals": { "pe": 33.5898123324397, "beta": 0.541658695720724, "epsTTM": 3.73, "fcfTTM": 6974000000, "growth": { "epsYoy": -0.5136897001303781, "revenueYoy": 0.0566865315852205 }, "sector": "Pharmaceutical Preparations", "margins": { "net": 0.1155654463390171, "gross": 0.1378197091273821, "operating": 0.1420511534603811 }, "website": "http://abbott.com", "industry": "Health care", "pegRatio": -0.653893047182265, "ebitdaTTM": 10384000000, "forwardPe": 22.0580985915493, "marketCap": 232169255381, "totalCash": 8522000000, "totalDebt": 15962000000, "debtEquity": 0.306196048340687, "quickRatio": 1.0225509214355, "revenueTTM": 31904000000, "companyName": "ABBOTT LABORATORIES", "priceToBook": 3.10651110130026, "currentRatio": 1.575897187196896, "dividendYield": 0.0192041540020031, "returnOnAssets": 0.04251957607279185, "returnOnEquity": 0.125148666794552, "analystOpinions": null, "businessSummary": "Abbott Laboratories, commonly known as Abbott, is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States (13% of 2024 revenues), diagnostic products (20% of 2024 revenues), nutritional products (22% of 2024 revenues), and medical devices (45% of 2024 revenues).", "enterpriseValue": 225569890000, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 115000, "sharesOutstanding": 1737682887, "enterpriseToEbitda": 21.72283224191063, "analystTargetMedian": null, "enterpriseToRevenue": 7.070269872116349, "operatingCashflowTTM": 9566000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:06:14.093Z" }, "results": [ { "id": "cmnr0l2w401lgp658uwu6x549", "runId": "cmnr0l2vz01lep658h281cyh8", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:02:06.000Z\",\"ticker\":\"ABT\",\"currency\":\"USD\",\"current_price\":103.56,\"target_price_6m\":112,\"target_price_12m\":118,\"recommendation\":\"BUY\",\"confidence\":0.62,\"thesis_bullets\":[\"Trading near 52-week low offers attractive entry for quality medtech franchise.\",\"Forward PE of 22x implies meaningful earnings recovery priced in by consensus.\",\"Medical devices segment (~45% revenue) provides durable mid-single-digit organic growth.\",\"Low leverage (D/E 0.31) and strong FCF ($7B) support dividends and reinvestment.\",\"EPS decline of 51% YoY is a headwind but likely reflects COVID-test normalization.\"],\"key_drivers\":[{\"driver\":\"Medical devices organic growth (FreeStyle Libre, structural heart)\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Post-COVID diagnostics revenue normalization\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Nutritional segment recovery and emerging market expansion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Gross margin expansion from product mix shift toward devices\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Share repurchase program supporting EPS accretion\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"FX headwinds from strong USD on ~60% international revenue\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Litigation overhang related to NEC infant formula lawsuits\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"New product pipeline cadence in diagnostics and devices\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"NEC litigation could result in material settlement/verdict costs.\",\"Prolonged diagnostics demand weakness beyond COVID normalization.\",\"Emerging-market macro deterioration impacting nutritional segment.\",\"Multiple compression if earnings recovery disappoints consensus.\",\"Regulatory risk on medical device approvals or pricing in key markets.\"],\"assumptions\":{\"revenue_cagr_3y\":0.06,\"ebit_margin_target\":0.18,\"wacc\":0.085,\"terminal_multiple\":23},\"scenarios\":{\"bear\":{\"target_price\":92,\"prob\":0.2,\"notes\":\"Earnings recovery stalls, litigation headwinds compress multiple to ~20x.\"},\"base\":{\"target_price\":118,\"prob\":0.55,\"notes\":\"EPS recovers to ~$4.70, market re-rates toward 25x forward earnings.\"},\"bull\":{\"target_price\":138,\"prob\":0.25,\"notes\":\"Strong device acceleration and margin expansion drive EPS above $5, multiple expands.\"}},\"method_notes\":\"Blended forward PE and EV/EBITDA valuation. Forward EPS ~$4.70 (consensus-implied from snapshot forward PE). Applied 25x base PE reflecting quality medtech premium but below 5-year historical avg given near-term headwinds. Cross-checked with FCF yield (~3%) and EV/EBITDA. 12M base target ~$118 implies ~14% upside, consistent with BUY. Confidence at 0.62 reflects mixed signals: defensive franchise near lows vs uncertain EPS trajectory. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:02:06.000Z", "model": "ai-equity-research-v1", "risks": [ "NEC litigation could result in material settlement/verdict costs.", "Prolonged diagnostics demand weakness beyond COVID normalization.", "Emerging-market macro deterioration impacting nutritional segment.", "Multiple compression if earnings recovery disappoints consensus.", "Regulatory risk on medical device approvals or pricing in key markets." ], "ticker": "ABT", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "EPS recovers to ~$4.70, market re-rates toward 25x forward earnings.", "target_price": 118 }, "bear": { "prob": 0.2, "notes": "Earnings recovery stalls, litigation headwinds compress multiple to ~20x.", "target_price": 92 }, "bull": { "prob": 0.25, "notes": "Strong device acceleration and margin expansion drive EPS above $5, multiple expands.", "target_price": 138 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.06, "terminal_multiple": 23, "ebit_margin_target": 0.18 }, "key_drivers": [ { "driver": "Medical devices organic growth (FreeStyle Libre, structural heart)", "impact": "HIGH", "direction": "POS" }, { "driver": "Post-COVID diagnostics revenue normalization", "impact": "HIGH", "direction": "NEG" }, { "driver": "Nutritional segment recovery and emerging market expansion", "impact": "MED", "direction": "POS" }, { "driver": "Gross margin expansion from product mix shift toward devices", "impact": "MED", "direction": "POS" }, { "driver": "Share repurchase program supporting EPS accretion", "impact": "MED", "direction": "POS" }, { "driver": "FX headwinds from strong USD on ~60% international revenue", "impact": "MED", "direction": "NEG" }, { "driver": "Litigation overhang related to NEC infant formula lawsuits", "impact": "MED", "direction": "NEG" }, { "driver": "New product pipeline cadence in diagnostics and devices", "impact": "MED", "direction": "POS" } ], "method_notes": "Blended forward PE and EV/EBITDA valuation. Forward EPS ~$4.70 (consensus-implied from snapshot forward PE). Applied 25x base PE reflecting quality medtech premium but below 5-year historical avg given near-term headwinds. Cross-checked with FCF yield (~3%) and EV/EBITDA. 12M base target ~$118 implies ~14% upside, consistent with BUY. Confidence at 0.62 reflects mixed signals: defensive franchise near lows vs uncertain EPS trajectory. Not investment advice.", "current_price": 103.56, "recommendation": "BUY", "thesis_bullets": [ "Trading near 52-week low offers attractive entry for quality medtech franchise.", "Forward PE of 22x implies meaningful earnings recovery priced in by consensus.", "Medical devices segment (~45% revenue) provides durable mid-single-digit organic growth.", "Low leverage (D/E 0.31) and strong FCF ($7B) support dividends and reinvestment.", "EPS decline of 51% YoY is a headwind but likely reflects COVID-test normalization." ], "target_price_6m": 112, "target_price_12m": 118 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 87289, "createdAt": "2026-04-09T05:06:14.108Z", "usage": { "inputTokens": 3601, "outputTokens": 1485, "costUsd": 0.05513 } }, { "id": "cmnr0l2w401ljp658rturggaf", "runId": "cmnr0l2vz01lep658h281cyh8", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity_Research_Analyst_Model\",\n \"as_of\": \"2026-04-08T20:02:06.000Z\",\n \"ticker\": \"ABT\",\n \"currency\": \"USD\",\n \"current_price\": 103.56,\n \"target_price_6m\": 105.0,\n \"target_price_12m\": 107.0,\n \"recommendation\": \"HOLD\",\n \"confidence\": 0.6,\n \"thesis_bullets\": [\n \"Diversified healthcare business with stable cash flows.\",\n \"Recent EPS decline offset by revenue growth potential.\",\n \"Strong balance sheet supports shareholder returns.\",\n \"Valuation near lows, but growth uncertainties remain.\",\n \"Mixed sector dynamics with regulatory and competitive risks.\"\n ],\n \"key_drivers\": [\n { \"driver\": \"Aging population driving medical device demand\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Competition in diagnostics segment\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n { \"driver\": \"Efficiency improvements in operations\", \"impact\": \"MED\", \"direction\": \"POS\" },\n { \"driver\": \"Currency exchange fluctuations\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n { \"driver\": \"Pipeline product launches and innovation\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n { \"driver\": \"Debt levels and interest rate sensitivity\", \"impact\": \"MED\", \"direction\": \"NEG\" }\n ],\n \"risks\": [\"Regulatory approval delays\", \"Competitive pressure in key segments\", \"Macroeconomic sensitivity\", \"Litigation and legal risks\"],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.05,\n \"ebit_margin_target\": 0.15,\n \"wacc\": 0.08,\n \"terminal_multiple\": 18\n },\n \"scenarios\": {\n \"bear\": { \"target_price\": 95.0, \"prob\": 0.3, \"notes\": \"Weak earnings and multiple contraction.\" },\n \"base\": { \"target_price\": 107.0, \"prob\": 0.5, \"notes\": \"Steady growth and margin improvement.\" },\n \"bull\": { \"target_price\": 120.0, \"prob\": 0.2, \"notes\": \"Strong product adoption and market expansion.\" }\n },\n \"method_notes\": \"Valuation based on DCF with assumed 5% revenue growth and 15% EBIT margin. Base case target $107 implies 3.3% upside, warranting HOLD. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:02:06.000Z", "model": "Equity_Research_Analyst_Model", "risks": [ "Regulatory approval delays", "Competitive pressure in key segments", "Macroeconomic sensitivity", "Litigation and legal risks" ], "ticker": "ABT", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady growth and margin improvement.", "target_price": 107 }, "bear": { "prob": 0.3, "notes": "Weak earnings and multiple contraction.", "target_price": 95 }, "bull": { "prob": 0.2, "notes": "Strong product adoption and market expansion.", "target_price": 120 } }, "confidence": 0.6, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.05, "terminal_multiple": 18, "ebit_margin_target": 0.15 }, "key_drivers": [ { "driver": "Aging population driving medical device demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Competition in diagnostics segment", "impact": "MED", "direction": "NEG" }, { "driver": "Efficiency improvements in operations", "impact": "MED", "direction": "POS" }, { "driver": "Currency exchange fluctuations", "impact": "LOW", "direction": "NEG" }, { "driver": "Pipeline product launches and innovation", "impact": "HIGH", "direction": "POS" }, { "driver": "Debt levels and interest rate sensitivity", "impact": "MED", "direction": "NEG" } ], "method_notes": "Valuation based on DCF with assumed 5% revenue growth and 15% EBIT margin. Base case target $107 implies 3.3% upside, warranting HOLD. Not investment advice.", "current_price": 103.56, "recommendation": "HOLD", "thesis_bullets": [ "Diversified healthcare business with stable cash flows.", "Recent EPS decline offset by revenue growth potential.", "Strong balance sheet supports shareholder returns.", "Valuation near lows, but growth uncertainties remain.", "Mixed sector dynamics with regulatory and competitive risks." ], "target_price_6m": 105, "target_price_12m": 107 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 377, "createdAt": "2026-04-09T05:06:14.108Z", "usage": { "inputTokens": 2119, "outputTokens": 4361, "costUsd": 0.002425 } }, { "id": "cmnr0l2w401lhp658d02e58m3", "runId": "cmnr0l2vz01lep658h281cyh8", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity-Research-Alpha-v1\",\n \"as_of\": \"2026-04-08T20:02:06.000Z\",\n \"ticker\": \"ABT\",\n \"currency\": \"USD\",\n \"current_price\": 103.56,\n \"target_price_6m\": 109.00,\n \"target_price_12m\": 115.00,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.75,\n \"thesis_bullets\": [\n \"Medical Devices segment, led by FreeStyle Libre, provides durable double-digit revenue growth.\",\n \"Diagnostics segment is stabilizing as COVID-19 testing headwinds finally fully roll off.\",\n \"Strong free cash flow generation supports consistent dividend growth and strategic tuck-in M&A.\",\n \"Forward P/E of 22x is reasonable given the high-quality, diversified healthcare portfolio.\",\n \"GLP-1 risks to diabetes care are overstated; CGM adoption continues to expand globally.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"FreeStyle Libre Sales Growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Structural Heart Pipeline Approvals\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"GLP-1 Drug Adoption\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Nutrition Segment Margin Recovery\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Foreign Exchange Headwinds\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Base Diagnostics Volume\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n }\n ],\n \"risks\": [\n \"Wider adoption of GLP-1 weight-loss drugs could reduce the long-term TAM for diabetes devices.\",\n \"Ongoing litigation and market share recovery challenges in the infant formula business.\",\n \"Regulatory delays for new medical device approvals in key markets.\",\n \"Strong USD could pressure international revenue translation.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.065,\n \"ebit_margin_target\": 0.215,\n \"wacc\": 0.075,\n \"terminal_multiple\": 22.0\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 90.00,\n \"prob\": 0.20,\n \"notes\": \"GLP-1 adoption severely impacts CGM growth and nutrition margins fail to recover.\"\n },\n \"base\": {\n \"target_price\": 115.00,\n \"prob\": 0.60,\n \"notes\": \"Steady mid-single-digit revenue growth with operating leverage driving EPS expansion.\"\n },\n \"bull\": {\n \"target_price\": 130.00,\n \"prob\": 0.20,\n \"notes\": \"Libre outpaces expectations and structural heart pipeline delivers blockbuster growth.\"\n }\n },\n \"method_notes\": \"Valuation based on a 10-year DCF and a 24x target P/E on NTM earnings, reflecting ABT's historical premium for diversified, defensive growth. The 11% upside supports a BUY rating. This is not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:02:06.000Z", "model": "Equity-Research-Alpha-v1", "risks": [ "Wider adoption of GLP-1 weight-loss drugs could reduce the long-term TAM for diabetes devices.", "Ongoing litigation and market share recovery challenges in the infant formula business.", "Regulatory delays for new medical device approvals in key markets.", "Strong USD could pressure international revenue translation." ], "ticker": "ABT", "currency": "USD", "scenarios": { "base": { "prob": 0.6, "notes": "Steady mid-single-digit revenue growth with operating leverage driving EPS expansion.", "target_price": 115 }, "bear": { "prob": 0.2, "notes": "GLP-1 adoption severely impacts CGM growth and nutrition margins fail to recover.", "target_price": 90 }, "bull": { "prob": 0.2, "notes": "Libre outpaces expectations and structural heart pipeline delivers blockbuster growth.", "target_price": 130 } }, "confidence": 0.75, "assumptions": { "wacc": 0.075, "revenue_cagr_3y": 0.065, "terminal_multiple": 22, "ebit_margin_target": 0.215 }, "key_drivers": [ { "driver": "FreeStyle Libre Sales Growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Structural Heart Pipeline Approvals", "impact": "MED", "direction": "POS" }, { "driver": "GLP-1 Drug Adoption", "impact": "MED", "direction": "NEG" }, { "driver": "Nutrition Segment Margin Recovery", "impact": "MED", "direction": "POS" }, { "driver": "Foreign Exchange Headwinds", "impact": "LOW", "direction": "NEG" }, { "driver": "Base Diagnostics Volume", "impact": "MED", "direction": "POS" } ], "method_notes": "Valuation based on a 10-year DCF and a 24x target P/E on NTM earnings, reflecting ABT's historical premium for diversified, defensive growth. The 11% upside supports a BUY rating. This is not investment advice.", "current_price": 103.56, "recommendation": "BUY", "thesis_bullets": [ "Medical Devices segment, led by FreeStyle Libre, provides durable double-digit revenue growth.", "Diagnostics segment is stabilizing as COVID-19 testing headwinds finally fully roll off.", "Strong free cash flow generation supports consistent dividend growth and strategic tuck-in M&A.", "Forward P/E of 22x is reasonable given the high-quality, diversified healthcare portfolio.", "GLP-1 risks to diabetes care are overstated; CGM adoption continues to expand globally." ], "target_price_6m": 109, "target_price_12m": 115 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-pro-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 20875, "createdAt": "2026-04-09T05:06:14.108Z", "usage": { "inputTokens": 2495, "outputTokens": 857, "costUsd": 0.015274 } }, { "id": "cmnr0l2w401lfp658mkc635uj", "runId": "cmnr0l2vz01lep658h281cyh8", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"AI Model Recommendation\",\"as_of\":\"2026-04-08T20:02:06.000Z\",\"ticker\":\"ABT\",\"currency\":\"USD\",\"current_price\":103.56,\"target_price_6m\":108,\"target_price_12m\":112,\"recommendation\":\"BUY\",\"confidence\":0.64,\"thesis_bullets\":[\"Libre CGM and electrophysiology support above-market device growth.\",\"COVID-testing drag is largely annualized, improving earnings comparability.\",\"Cash generation and balance sheet support dividends, buybacks, and bolt-on deals.\",\"Valuation remains above broad medtech peers, limiting rerating potential.\",\"Mixed growth and multiple support suggest modest upside, not a deep-value setup.\"],\"key_drivers\":[{\"driver\":\"FreeStyle Libre adoption\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Electrophysiology and structural heart growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Diagnostics normalization\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Nutrition pricing and recovery\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Margin recovery from mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Defensive cash generation\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Premium valuation multiple\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"China pricing and FX pressure\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"CGM competition compresses pricing or share.\",\"Regulatory, quality, or recall events disrupt sales.\",\"China reimbursement and FX pressure margins.\",\"Procedure volumes or nutrition demand weaken.\"],\"assumptions\":{\"revenue_cagr_3y\":0.058,\"ebit_margin_target\":0.2,\"wacc\":0.078,\"terminal_multiple\":22},\"scenarios\":{\"bear\":{\"target_price\":94,\"prob\":0.25,\"notes\":\"CGM growth cools and margins stay pressured, keeping shares de-rated.\"},\"base\":{\"target_price\":112,\"prob\":0.5,\"notes\":\"Devices grow steadily and margins recover modestly over the next year.\"},\"bull\":{\"target_price\":128,\"prob\":0.25,\"notes\":\"Libre and electrophysiology outgrow expectations, driving faster EPS recovery.\"}},\"method_notes\":\"Blended normalized EPS and multiple-based valuation using snapshot fundamentals and conservative recovery assumptions; 12M base implies ~8% upside, supporting BUY. Snapshot quote fields kept authoritative; no sell-side targets used; not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:02:06.000Z", "model": "AI Model Recommendation", "risks": [ "CGM competition compresses pricing or share.", "Regulatory, quality, or recall events disrupt sales.", "China reimbursement and FX pressure margins.", "Procedure volumes or nutrition demand weaken." ], "ticker": "ABT", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Devices grow steadily and margins recover modestly over the next year.", "target_price": 112 }, "bear": { "prob": 0.25, "notes": "CGM growth cools and margins stay pressured, keeping shares de-rated.", "target_price": 94 }, "bull": { "prob": 0.25, "notes": "Libre and electrophysiology outgrow expectations, driving faster EPS recovery.", "target_price": 128 } }, "confidence": 0.64, "assumptions": { "wacc": 0.078, "revenue_cagr_3y": 0.058, "terminal_multiple": 22, "ebit_margin_target": 0.2 }, "key_drivers": [ { "driver": "FreeStyle Libre adoption", "impact": "HIGH", "direction": "POS" }, { "driver": "Electrophysiology and structural heart growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Diagnostics normalization", "impact": "MED", "direction": "POS" }, { "driver": "Nutrition pricing and recovery", "impact": "MED", "direction": "POS" }, { "driver": "Margin recovery from mix", "impact": "HIGH", "direction": "POS" }, { "driver": "Defensive cash generation", "impact": "MED", "direction": "POS" }, { "driver": "Premium valuation multiple", "impact": "HIGH", "direction": "NEG" }, { "driver": "China pricing and FX pressure", "impact": "MED", "direction": "NEG" } ], "method_notes": "Blended normalized EPS and multiple-based valuation using snapshot fundamentals and conservative recovery assumptions; 12M base implies ~8% upside, supporting BUY. Snapshot quote fields kept authoritative; no sell-side targets used; not investment advice.", "current_price": 103.56, "recommendation": "BUY", "thesis_bullets": [ "Libre CGM and electrophysiology support above-market device growth.", "COVID-testing drag is largely annualized, improving earnings comparability.", "Cash generation and balance sheet support dividends, buybacks, and bolt-on deals.", "Valuation remains above broad medtech peers, limiting rerating potential.", "Mixed growth and multiple support suggest modest upside, not a deep-value setup." ], "target_price_6m": 108, "target_price_12m": 112 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_0f1fb2ab70851d670069d734edd88481939e170ab346ee4869", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 40329, "createdAt": "2026-04-09T05:06:14.108Z", "usage": { "inputTokens": 2391, "outputTokens": 2578, "costUsd": 0.040276 } }, { "id": "cmnr0l2w401lip658k26wa0hz", "runId": "cmnr0l2vz01lep658h281cyh8", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Analyst\",\n \"as_of\": \"2026-04-08T20:02:06.000Z\",\n \"ticker\": \"ABT\",\n \"currency\": \"USD\",\n \"current_price\": 103.56,\n \"target_price_6m\": 112,\n \"target_price_12m\": 118,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"FreeStyle Libre drives diabetes segment growth\",\n \"Diversified mix across devices and diagnostics\",\n \"Stable cash flow supports dividend growth\",\n \"Forward P/E of 22x limits multiple expansion\",\n \"EPS decline offers entry near 52-week low\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Diabetes care product adoption\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Structural heart device sales\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Operating margin expansion\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Nutrition segment competition\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Payer pricing pressure\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"New product regulatory wins\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Valuation multiple contraction\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"FX volatility on int'l sales\",\n \"impact\": \"LOW\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Competition in diabetes and nutrition\",\n \"Regulatory delays on new devices\",\n \"Payer reimbursement cuts\",\n \"Supply chain cost inflation\",\n \"Macro impact on elective procedures\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.065,\n \"ebit_margin_target\": 0.17,\n \"wacc\": 0.085,\n \"terminal_multiple\": 19\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 88,\n \"prob\": 0.3,\n \"notes\": \"Growth slows amid competition and FX headwinds.\"\n },\n \"base\": {\n \"target_price\": 118,\n \"prob\": 0.5,\n \"notes\": \"Steady execution on core franchises and margins.\"\n },\n \"bull\": {\n \"target_price\": 142,\n \"prob\": 0.2,\n \"notes\": \"Accelerated Libre adoption and margin upside.\"\n }\n },\n \"method_notes\": \"DCF using 6.5% rev CAGR, 17% EBIT margin, 8.5% WACC and 19x terminal. 14% 12M upside supports BUY. Consensus not used as input. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:02:06.000Z", "model": "AI Equity Analyst", "risks": [ "Competition in diabetes and nutrition", "Regulatory delays on new devices", "Payer reimbursement cuts", "Supply chain cost inflation", "Macro impact on elective procedures" ], "ticker": "ABT", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution on core franchises and margins.", "target_price": 118 }, "bear": { "prob": 0.3, "notes": "Growth slows amid competition and FX headwinds.", "target_price": 88 }, "bull": { "prob": 0.2, "notes": "Accelerated Libre adoption and margin upside.", "target_price": 142 } }, "confidence": 0.62, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.065, "terminal_multiple": 19, "ebit_margin_target": 0.17 }, "key_drivers": [ { "driver": "Diabetes care product adoption", "impact": "HIGH", "direction": "POS" }, { "driver": "Structural heart device sales", "impact": "HIGH", "direction": "POS" }, { "driver": "Operating margin expansion", "impact": "MED", "direction": "POS" }, { "driver": "Nutrition segment competition", "impact": "MED", "direction": "NEG" }, { "driver": "Payer pricing pressure", "impact": "MED", "direction": "NEG" }, { "driver": "New product regulatory wins", "impact": "MED", "direction": "POS" }, { "driver": "Valuation multiple contraction", "impact": "HIGH", "direction": "NEG" }, { "driver": "FX volatility on int'l sales", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF using 6.5% rev CAGR, 17% EBIT margin, 8.5% WACC and 19x terminal. 14% 12M upside supports BUY. Consensus not used as input. not investment advice.", "current_price": 103.56, "recommendation": "BUY", "thesis_bullets": [ "FreeStyle Libre drives diabetes segment growth", "Diversified mix across devices and diagnostics", "Stable cash flow supports dividend growth", "Forward P/E of 22x limits multiple expansion", "EPS decline offers entry near 52-week low" ], "target_price_6m": 112, "target_price_12m": 118 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "6958a61b-d0fd-9b2b-8da7-a4386152086f", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 22343, "createdAt": "2026-04-09T05:06:14.108Z", "usage": { "inputTokens": 2731, "outputTokens": 2691, "costUsd": 0.048558 } } ] } }